Risk Management And Error Prevention - NAPLEX

1. In a community pharmacy, a 28-year-old male (75 kg) presents a prescription for promethazine-codeine syrup 5 mL PO q6h PRN cough, 240 mL, for a "cold," and asks to pay cash; his profile shows a recent fill of oxycodone IR 10 mg #120 two weeks ago from a different prescriber. Current meds: oxycodone IR 10 mg PO q6h PRN, cyclobenzaprine 10 mg PO TID PRN. Labs: SCr 0.9 mg/dL, AST/ALT 33/35 U/L, INR 1.0, A1c 5.5%; allergies: none. The risk is controlled substance misuse/diversion and additive CNS/respiratory depression. How should the pharmacist ensure compliance with controlled substance regulations?
   Answer: Check PDMP, assess for red flags, and contact the prescriber to verify indication/therapy appropriateness before dispensing or refusing per policy This question tests evaluation of controlled substance prescriptions for legitimacy. The key risk element is the promethazine-codeine request with recent opioid fills, indicating potential misuse and CNS depression. Checking PDMP, assessing red flags, and verifying with prescriber is the best choice as it ensures compliant dispensing. Filling without review or altering dose enables diversion, while casual instructions lack documentation. Assuming low risk ignores patterns. A clinical pearl is to scrutinize combinations and histories in controlled substances. Pharmacists should apply corresponding responsibility frameworks for risk assessment.
2. In a community pharmacy, a 68-year-old male (82 kg) is discharged after DVT treatment with a new prescription for enoxaparin 120 mg subcutaneously every 12 hours for 7 days. Current medications: lisinopril 20 mg PO daily, metformin 1000 mg PO BID, aspirin 81 mg PO daily. Allergies: penicillin (rash). Labs from discharge: SCr 2.1 mg/dL (high; normal ~0.7–1.3), AST 28 U/L, ALT 25 U/L, A1c 7.8% (high; goal usually <7%), INR 1.1. The dose appears higher than expected and renal function is reduced, creating a high-alert anticoagulant dosing risk. Which action should the pharmacist take to mitigate this risk?
   Answer: Hold dispensing and contact the prescriber to verify indication and weight-based/renal-adjusted dosing before dispensing This question tests the pharmacist's ability to identify and manage high-alert anticoagulant dosing risks in patients with renal impairment. The key patient-specific factor is the elevated serum creatinine of 2.1 mg/dL, indicating significantly reduced renal function that requires enoxaparin dose adjustment. Option B is the BEST choice because enoxaparin requires renal dose adjustment when CrCl < 30 mL/min, and the prescribed dose of 120 mg every 12 hours appears to be a full treatment dose that may be excessive for this patient's renal function. Option A is incorrect because enoxaparin absolutely requires renal adjustment regardless of duration when kidney function is impaired, as it is primarily renally eliminated. Option C is dangerous because therapeutic substitution of anticoagulants without prescriber authorization violates pharmacy practice standards and creates additional safety risks. Option D is incorrect and dangerous because enoxaparin must be given subcutaneously, never intramuscularly, as IM administration can cause hematoma formation. The clinical pearl is that all low molecular weight heparins require renal dose adjustment when CrCl < 30 mL/min, and pharmacists must calculate creatinine clearance and verify appropriate dosing before dispensing any anticoagulant in patients with elevated serum creatinine.
3. In a hospital, a 52-year-old male (95 kg) is ordered concentrated potassium chloride (KCl) IV for hypokalemia: "KCl 40 mEq IV push now." Current meds: hydrochlorothiazide 25 mg PO daily, lisinopril 20 mg PO daily. Labs: K 2.9 mEq/L (low), SCr 1.2 mg/dL, AST/ALT 21/20 U/L, INR 1.0, A1c 5.9%; allergies: none. The risk is fatal arrhythmia from inadvertent IV push of KCl (high-alert medication administration error). Which action should the pharmacist take to mitigate this risk?
   Answer: Verify the order with the prescriber and require KCl to be diluted and administered via infusion pump per protocol (no IV push), with appropriate rate limits This question tests protocols for high-alert electrolytes to prevent administration errors. The key risk element is the IV push order for concentrated KCl, risking fatal arrhythmia in a hypokalemic patient on diuretics. Verifying and requiring diluted infusion with pump limits is the best choice as it aligns with safe administration guidelines. Dispensing as push or substituting without checks endangers the patient, while stocking concentrates increases risks. Rapid correction isn't always safest. A pearl is that KCl demands restricted access and protocols. Pharmacists should enforce verification and safeguards for high-alert meds.
4. In a community pharmacy, a 46-year-old female (69 kg) requests an early refill for oxycodone ER 20 mg tablets, 1 tablet PO BID, stating she is traveling; the PDMP shows multiple recent fills of similar opioids from different prescribers. Current meds: oxycodone ER 20 mg BID, diazepam 5 mg PO BID PRN. Labs: SCr 0.8 mg/dL, AST/ALT 35/37 U/L, INR 1.0, A1c 5.6%; allergies: none. The risk is controlled substance diversion and unsafe opioid/benzodiazepine combination. How should the pharmacist ensure compliance with controlled substance regulations?
   Answer: Check PDMP, evaluate for corresponding responsibility/red flags, contact prescriber(s) as needed, document rationale, and follow policy on early refills or refusal This question tests assessment of early refill requests for controlled substances. The key risk element is the travel excuse with PDMP showing multiple opioid sources, indicating diversion and unsafe combinations. Checking PDMP, evaluating red flags, and contacting prescribers is the best choice as it upholds responsibility. Filling without review or altering strength/dosing enables misuse. Recommending more frequent use worsens risks. A clinical pearl is to scrutinize patterns in early requests. Pharmacists should document decisions using compliance frameworks.
5. In a hospital pharmacy, a 6-year-old female (20 kg) is prescribed IV morphine for post-operative pain: morphine 0.05 mg/kg IV every 2 hours as needed. Current medications: acetaminophen 15 mg/kg PO every 6 hours, ondansetron 0.15 mg/kg IV every 8 hours PRN. Allergies: none. Labs: SCr 0.4 mg/dL, AST 26 U/L, ALT 18 U/L, A1c not applicable, INR 1.0. A nurse requests a morphine dose from an adult vial concentration (10 mg/mL), creating a high-alert pediatric dosing and concentration error risk. Which action should the pharmacist take to mitigate this risk?
   Answer: Prepare and dispense a patient-specific, pharmacy-diluted syringe (standard concentration) with barcode labeling and require an independent double-check prior to administration This question addresses pediatric high-alert medication safety and the risks of using adult-concentration products in children. The key risk factors are the small pediatric dose (1 mg for a 20 kg child), the high concentration of adult morphine vials (10 mg/mL), and the potential for 10-fold dosing errors. Option B is the BEST approach because pharmacy-prepared, patient-specific syringes with appropriate dilution eliminate bedside calculation errors, barcode scanning ensures correct patient matching, and independent double-checks catch preparation errors before they reach the patient. Option A is dangerous because expecting nurses to accurately measure 0.1 mL from a concentrated vial invites calculation and measurement errors. Option C is inappropriate because morphine must be given IV as ordered for acute pain control, and route changes require prescriber authorization. Option D doesn't address the immediate safety concern and unnecessarily delays pain management. The transferable safety principle is that pediatric doses of high-alert medications should be prepared in the pharmacy using standardized concentrations and volumes that minimize bedside manipulation, with technology and independent verification providing additional safety layers.
6. In a busy community pharmacy, a prescription is received for hydrOXYzine 25 mg PO every 6 hours as needed for anxiety for a 59-year-old female (70 kg). Her current medications: sertraline 100 mg PO daily, trazodone 50 mg PO at bedtime, hydrochlorothiazide 25 mg PO daily. Allergies: none. Labs: SCr 1.0 mg/dL, AST 30 U/L, ALT 28 U/L, A1c 6.8%, INR 1.0. The technician selects hydrALAZINE 25 mg tablets due to look-alike/sound-alike risk, creating a potential dispensing error. What is the most effective strategy to prevent this medication error?
   Answer: Use Tall Man lettering and require pharmacist product verification against the original prescription before dispensing This question tests strategies to prevent look-alike/sound-alike (LASA) medication errors in pharmacy practice. The critical risk is the similarity between hydrOXYzine (an antihistamine/anxiolytic) and hydrALAZINE (an antihypertensive), which can lead to serious patient harm if confused. Option A is the BEST strategy because Tall Man lettering visually differentiates the drug names at the point of selection, and requiring pharmacist verification against the original prescription provides a critical safety check before the wrong medication reaches the patient. Option B is insufficient because relying solely on patient counseling at pickup may miss the error if the patient is unfamiliar with the medication appearance. Option C is clinically inappropriate and dangerous because hydralazine is not indicated for anxiety and could cause hypotension in a patient not requiring blood pressure treatment. Option D actually increases error risk by storing LASA medications together, violating safety best practices. The transferable safety principle is that LASA error prevention requires multiple strategies including Tall Man lettering, physical separation of similar drugs, barcode scanning, and independent double-checks, with pharmacist verification serving as the final safety barrier before dispensing.
7. In an emergency department, a 6-year-old female (20 kg) is ordered IV insulin for DKA; the order reads insulin regular infusion 0.1 units/kg/hour. Current meds: none. Labs: SCr 0.4 mg/dL, AST/ALT 18/16 U/L, A1c 12.4%, INR 1.0; allergies: none. The risk is a high-alert medication dosing error if the infusion is entered as 0.1 units/hour instead of 2 units/hour. What is the best practice for handling this high-alert medication?
   Answer: Require pharmacist verification of weight-based dose and smart-pump drug library use with independent double-check before starting the infusion This question tests safeguards for pediatric high-alert medication infusions to prevent dosing errors. The key risk element is the weight-based insulin order in a child with DKA, where misprogramming could cause severe hypoglycemia if units/hour is mistaken for units/kg/hour. Requiring pharmacist verification and smart-pump use with double-checks is the best choice as it ensures accurate calculation and administration. Allowing free-text programming increases error risk, while rounding down or delaying ignores clinical needs. Substituting without protocol is unsafe. A clinical pearl is that weight-based dosing in pediatrics demands multiple verifications. Pharmacists should use a framework of technology and human checks to prevent high-alert errors in vulnerable populations.
8. In an anticoagulation clinic, a 70-year-old female (58 kg) on warfarin for mechanical mitral valve reports starting trimethoprim-sulfamethoxazole yesterday from urgent care. Current meds: warfarin 4 mg PO daily, amiodarone 200 mg PO daily, furosemide 20 mg PO daily. Labs: INR 2.8 (goal 2.5–3.5), SCr 1.0 mg/dL, AST/ALT 25/22 U/L, A1c 6.0%; allergies: none. The risk is a major warfarin interaction increasing INR and bleeding. Which action should the pharmacist take to mitigate this risk?
   Answer: Contact the prescriber to consider an alternative antibiotic and/or empiric warfarin dose adjustment, and arrange an earlier INR check within 2–3 days This question tests management of drug interactions in anticoagulation to prevent bleeding. The key risk element is the warfarin-trimethoprim/sulfamethoxazole interaction elevating INR in a patient with mechanical valve and amiodarone. Contacting the prescriber for alternatives and early INR check is the best choice as it proactively mitigates risk. Stopping warfarin or switching to rivaroxaban without input is unsafe, especially in valves, while monitoring A1c is irrelevant. Assuming no action risks hemorrhage. A clinical pearl is to anticipate interactions with high-risk drugs like warfarin. Pharmacists should use a framework of alert, communicate, and monitor for interaction management.
9. In an outpatient clinic pharmacy, a 67-year-old female (59 kg) with rheumatoid arthritis is on hydroxychloroquine 200 mg PO BID chronically and reports new blurry vision. Current meds: hydroxychloroquine 200 mg BID, methotrexate 15 mg PO weekly, folic acid 1 mg daily, prednisone 5 mg daily. Labs: SCr 1.1 mg/dL, AST/ALT 32/35 U/L, INR 1.0, A1c 6.2%; allergies: none. The risk is an adverse drug reaction (retinopathy) that can be irreversible if not monitored. Which monitoring parameter is critical to prevent adverse events?
   Answer: Baseline and periodic ophthalmologic retinal exams (per guideline intervals) and assessment for visual changes This question evaluates risk management for adverse drug reactions through appropriate monitoring of hydroxychloroquine, focusing on its potential for ocular toxicity. The key patient-specific factor is the chronic use of hydroxychloroquine at 200 mg BID in a 67-year-old female reporting blurry vision, which signals possible retinopathy that can progress to irreversible vision loss if not detected early. Baseline and periodic ophthalmologic retinal exams per guideline intervals, along with assessing visual changes, is the best choice as it directly targets the primary risk of retinopathy, enabling timely discontinuation if toxicity is identified. Choice B is incorrect because hydroxychloroquine does not significantly affect coagulation, making frequent INR monitoring unnecessary and irrelevant to the main adverse event. Choices C and D are suboptimal as serum troponin is not indicated for routine myocarditis monitoring with this drug, and monthly A1c is inappropriate since hydroxychloroquine is more associated with hypoglycemia than hyperglycemia. A transferable clinical pearl is to prioritize drug-specific monitoring parameters based on evidence-based guidelines to prevent irreversible harms. In pharmacy practice, using decision frameworks like REMS protocols or patient risk stratification ensures proactive adverse event prevention and optimal therapeutic management.
10. On a medical-surgical unit, a 79-year-old male (90 kg) with chronic kidney disease is started on vancomycin for suspected MRSA cellulitis. Current meds: furosemide 40 mg PO daily, losartan 50 mg PO daily, insulin lispro sliding scale. Labs: SCr 2.2 mg/dL (elevated; baseline 1.8), AST/ALT 20/18 U/L, A1c 7.9%, INR 1.1; allergies: none. The risk is nephrotoxicity from vancomycin, especially with worsening renal function. Which monitoring parameter is critical to prevent adverse events?
    Answer: Vancomycin AUC-guided monitoring (or troughs per protocol) along with serial SCr/urine output to adjust dosing This question tests monitoring for high-risk medications to prevent adverse events like nephrotoxicity. The key risk element is vancomycin use in an elderly patient with baseline renal impairment, increasing toxicity risk without proper dosing adjustments. AUC-guided monitoring with serial SCr and urine output is the best choice as it allows timely dose adjustments to prevent kidney injury. Daily potassium monitoring targets the wrong risk, as hyperkalemia isn't primary with vancomycin, while INR or A1c checks are irrelevant here. Focusing on unrelated labs overlooks nephrotoxicity. A clinical pearl is to prioritize drug-specific monitoring parameters for high-risk agents like vancomycin. Pharmacists should use a framework of baseline assessment, ongoing surveillance, and adjustment to manage risks effectively.
11. In a hospital, a 61-year-old male (80 kg) on amiodarone is started on IV levofloxacin for pneumonia. Current meds: amiodarone 200 mg PO daily, carvedilol 12.5 mg PO BID, spironolactone 25 mg PO daily. Labs: SCr 1.4 mg/dL, AST/ALT 45/50 U/L (mildly elevated), INR 1.0, A1c 6.3%; allergies: none. The risk is QT prolongation and torsades with additive QT-prolonging drugs and electrolyte abnormalities. Which monitoring parameter is critical to prevent adverse events?
    Answer: Serial ECG/QTc monitoring and electrolytes (K, Mg) with correction of abnormalities during therapy This question tests monitoring for drug-induced QT prolongation to prevent arrhythmias. The key risk element is levofloxacin-amiodarone combination with potential electrolyte issues, increasing torsades risk in a cardiac patient. Serial ECG/QTc and electrolyte monitoring is the best choice as it detects and corrects abnormalities promptly. A1c, INR, or amylase monitoring targets irrelevant risks here. Assuming universal INR effects is incorrect. A clinical pearl is to prioritize cardiac monitoring for QT-prolonging drugs. Pharmacists should use a risk-based monitoring framework for adverse event prevention.
12. In a community pharmacy, a 27-year-old female (65 kg) brings a new prescription for lamotrigine with directions: "Take 100 mg PO twice daily." Current medications: valproic acid 500 mg PO BID, ethinyl estradiol/levonorgestrel 1 tablet PO daily. Allergies: none. Labs: SCr 0.7 mg/dL, AST 40 U/L (mildly high; normal ~10–40), ALT 38 U/L, A1c 5.6%, INR 1.0. Starting lamotrigine at a high dose with concurrent valproic acid increases risk of serious rash (e.g., SJS/TEN) due to drug interaction and titration requirements. What is the most effective strategy to prevent this medication error?
    Answer: Contact the prescriber to verify appropriate lamotrigine titration for use with valproic acid before dispensing and document the intervention This question evaluates prevention of serious adverse drug reactions through proper drug interaction management and titration protocols. The critical risk is that valproic acid significantly inhibits lamotrigine metabolism, requiring much slower titration (typically starting at 25 mg every other day) to prevent Stevens-Johnson Syndrome and toxic epidermal necrolysis. Option B is the BEST action because it addresses the safety concern through appropriate prescriber communication and ensures proper titration before dispensing a potentially dangerous dose. Option A is inadequate because simply counseling about rash doesn't prevent the serious reaction that can occur with improper dosing. Option C is inappropriate and illegal as therapeutic substitution requires prescriber authorization, and arbitrarily switching antiepileptic drugs could result in seizures. Option D is incorrect because taking with food doesn't prevent immunologic reactions like SJS/TEN, and proceeding with dispensing could result in a life-threatening reaction. The clinical pearl is that lamotrigine requires specific titration schedules that vary dramatically based on concurrent medications: slowest with valproic acid (enzyme inhibitor), standard alone, and fastest with enzyme inducers like carbamazepine.
13. During hospital admission medication reconciliation, a 74-year-old female (60 kg) is transferred from a skilled nursing facility for pneumonia. Facility med list: warfarin 5 mg PO daily, amiodarone 200 mg PO daily, levothyroxine 75 mcg PO daily, sertraline 50 mg PO daily. Hospital admission orders include: warfarin 7.5 mg PO daily, amiodarone 200 mg PO daily, ceftriaxone 1 g IV daily. Allergies: sulfonamides (hives). Labs: INR 3.4 (high; goal 2–3), SCr 0.9 mg/dL, AST 22 U/L, ALT 20 U/L, A1c 6.1%. The transition creates a high-risk discrepancy with warfarin dosing and supratherapeutic INR. What is the best approach to reconcile these medication lists?
    Answer: Clarify the intended warfarin dose with the prescriber using the SNF record and current INR, and recommend holding/adjusting warfarin per protocol This question evaluates medication reconciliation skills for high-risk anticoagulants during care transitions. The critical risk factor is the discrepancy between the SNF warfarin dose (5 mg daily) and the hospital admission order (7.5 mg daily), combined with a supratherapeutic INR of 3.4. Option C is the BEST approach because it addresses the medication discrepancy through proper communication channels while prioritizing patient safety by recommending appropriate warfarin management based on the elevated INR. Option A is incorrect because continuing the higher warfarin dose with an already elevated INR could lead to serious bleeding complications, and infections typically increase (not decrease) warfarin requirements. Option B is inappropriate because abruptly discontinuing amiodarone won't immediately resolve the drug interaction, and unilateral medication changes without prescriber involvement are outside pharmacy scope. Option D is dangerous because ignoring facility medication lists during transitions is a major cause of medication errors and violates reconciliation standards. The transferable principle is that medication reconciliation requires comparing all medication sources, identifying discrepancies, and resolving them through prescriber communication, especially for high-alert medications like warfarin where dosing errors can be fatal.
14. In an outpatient pharmacy, a 65-year-old female (62 kg) is prescribed celecoxib 200 mg PO BID for arthritis, but the prescription is entered as citalopram 20 mg PO daily due to similar spelling. Current meds: warfarin 3 mg PO daily, lisinopril 10 mg PO daily, metformin 500 mg PO BID. Labs: SCr 1.0 mg/dL, AST/ALT 23/20 U/L, INR 2.6, A1c 7.3%; allergies: none. The risk is look-alike/sound-alike error leading to missed pain control and potential SSRI adverse effects/interaction risk. What is the most effective strategy to prevent this medication error?
    Answer: Require indication entry and pharmacist clinical check against diagnosis and dose, plus barcode/NDC verification at filling for celecoxib vs citalopram This question tests LASA error prevention in dispensing workflows. The key risk element is celecoxib-citalopram confusion, leading to untreated pain and interaction risks in a warfarin patient. Requiring indication checks and barcode verification is the best choice as it ensures accuracy and clinical appropriateness. Dispensing by insurance or patient query is unreliable, while bypassing verification invites errors. Assuming coverage dictates choice overlooks safety. A pearl is that LASA safeguards include clinical and tech verifications. Pharmacists should build layered defenses in processes to avert such errors.
15. On a medical-surgical unit, a 45-year-old female (95 kg) with type 2 diabetes is ordered insulin regular U-500 using a concentrated insulin pen for severe insulin resistance: 80 units subcutaneously before breakfast and 60 units before dinner. Current medications: metformin 1000 mg PO BID, atorvastatin 40 mg PO nightly, lisinopril 10 mg PO daily. Allergies: none. Labs: A1c 11.2% (high), SCr 0.9 mg/dL, AST 24 U/L, ALT 26 U/L, INR 1.0. Because U-500 is a high-alert medication with concentration-related dosing errors, what is the best practice for handling this high-alert medication?
    Answer: Require independent double-check of product and dose in units, ensure use of the dedicated U-500 pen/syringe, and provide staff/patient education before first dose This question evaluates high-alert medication safety practices for concentrated insulin products. The key risk factor is that U-500 insulin is five times more concentrated than standard U-100 insulin, creating potential for severe hypoglycemia or hyperglycemia if dosed incorrectly. Option B is the BEST practice because it implements multiple safety layers: independent double-checks prevent calculation errors, dedicated U-500 devices prevent syringe mix-ups, and comprehensive education ensures all parties understand the concentration difference. Option A is dangerous because unilaterally converting doses between concentrations without prescriber involvement could result in significant under- or overdosing. Option C increases error risk by allowing widespread storage of a high-alert medication without proper safeguards. Option D is incorrect because insulin doses must always be documented in units, not volume, to prevent confusion and ensure accurate dosing regardless of concentration. The critical safety principle is that concentrated insulin products require special handling protocols including restricted storage, dedicated delivery devices, independent verification, and extensive education to prevent the catastrophic errors that can occur with these high-alert medications.
16. In a long-term care pharmacy, a 76-year-old female (54 kg) is receiving levothyroxine 88 mcg PO daily; the facility sends a refill request, but the eMAR shows both levothyroxine 88 mcg daily and liothyronine 25 mcg daily started during a recent hospitalization. Current meds: levothyroxine 88 mcg daily, liothyronine 25 mcg daily (per eMAR), calcium carbonate 500 mg BID, ferrous sulfate 325 mg daily. Labs: SCr 0.9 mg/dL, AST/ALT 20/18 U/L, INR 1.0, A1c 5.7%; allergy: none. The risk is unintended duplicate thyroid hormone therapy and administration timing interactions with calcium/iron. Which action should the pharmacist take to mitigate this risk?
    Answer: Clarify with the prescriber whether liothyronine is intended, reconcile to a single thyroid regimen, and ensure administration separation from calcium/iron is documented This question tests reconciliation of thyroid therapies to prevent duplication. The key risk element is unintended levothyroxine-liothyronine overlap with absorption interactions from calcium/iron in an elderly patient. Clarifying intent and documenting separation is the best choice as it ensures safe, intentional regimen. Continuing both or stopping without notification risks toxicity or undertreatment, while advising co-administration worsens absorption. Assuming preference ignores evidence. A pearl is to verify post-hospital changes in chronic therapies. Pharmacists should reconcile with a focus on interactions and documentation.
17. During admission medication reconciliation in a hospital, a 66-year-old male (88 kg) with CAD reports taking clopidogrel 75 mg PO daily at home; the transfer paperwork from a rehab facility lists prasugrel 10 mg PO daily. Current inpatient orders include aspirin 81 mg PO daily, atorvastatin 80 mg PO nightly, metoprolol succinate 50 mg PO daily. Labs: SCr 1.0 mg/dL, AST/ALT 34/30 U/L, INR 1.0, A1c 6.8%; allergies: none. The risk is unintended antiplatelet switch and bleeding or thrombosis if therapy is incorrect. What is the best approach to reconcile these medication lists?
    Answer: Verify the intended P2Y12 inhibitor and indication (e.g., recent PCI) using patient interview, prior records, and prescriber confirmation, then document the correct agent This question tests medication reconciliation to resolve discrepancies in high-risk therapies like antiplatelets. The key risk element is the conflicting clopidogrel and prasugrel listings, potentially leading to bleeding or thrombosis in a CAD patient post-PCI. Verifying the intended agent via multiple sources and documenting is the best choice as it ensures accurate therapy continuation. Continuing both risks bleeding, while discontinuing all or automatic substitution ignores indication and safety. Assuming potency without verification is erroneous. A pearl is to cross-verify sources in reconciliation for high-risk drugs. Pharmacists should employ a systematic approach: gather data, clarify, and document to prevent transition errors.
18. During medication reconciliation at a hospital admission, a 58-year-old male (92 kg) with type 2 diabetes reports using insulin glargine 30 units SQ nightly at home; the outpatient clinic medication list shows insulin degludec 30 units SQ nightly, and the inpatient orders currently include both glargine 30 units nightly and degludec 30 units nightly. Current meds: metformin 1000 mg PO BID, lisinopril 10 mg PO daily. Labs: SCr 1.0 mg/dL, AST/ALT 25/23 U/L, A1c 9.2%, INR 1.0; allergies: none. The risk is duplicate basal insulin causing severe hypoglycemia. What is the best approach to reconcile these medication lists?
    Answer: Confirm the patient's actual home basal insulin product and last dose, discontinue the unintended duplicate, and document the reconciled regimen in the chart This question tests reconciliation to prevent duplicate high-risk medications like insulins. The key risk element is conflicting glargine and degludec orders, potentially causing hypoglycemia in a diabetic patient. Confirming home regimen and discontinuing duplicate is the best choice as it ensures accurate therapy. Continuing both or holding all risks harm, while interchanging automatically ignores preferences. Assuming coverage needs duplicates is erroneous. A pearl is to verify patient-reported use in insulin reconciliation. Pharmacists should use multi-source confirmation frameworks at admissions.
19. In an outpatient pharmacy, a 32-year-old male (78 kg) presents a new prescription for hydromorphone 4 mg tablets, 1 tablet PO every 4 hours as needed, #180, written by a prescriber the pharmacy has not seen before. Current meds on profile: sertraline 100 mg PO daily, gabapentin 300 mg PO TID, ibuprofen 600 mg PO TID PRN. Labs from recent clinic note: SCr 0.9 mg/dL, AST/ALT 30/27 U/L, INR 1.0, A1c 5.4%; allergies: none. Setting: community pharmacy; the risk is controlled substance diversion and non-compliant dispensing. How should the pharmacist ensure compliance with controlled substance regulations?
    Answer: Contact the prescriber to verify legitimacy, check the state PDMP, and ensure quantity/directions are appropriate before dispensing This question tests corresponding responsibility in dispensing controlled substances to prevent diversion. The key risk element is a new high-quantity hydromorphone prescription from an unfamiliar prescriber, with potential for misuse in a patient on multiple CNS depressants. Contacting the prescriber, checking PDMP, and verifying appropriateness is the best choice as it fulfills legal and safety obligations before dispensing. Filling immediately risks non-compliance and harm from unverified legitimacy, while changing to another opioid without contact violates prescribing authority. Accepting verbal authorization from a friend or deferring verification enables diversion. A clinical pearl is to assess red flags like unfamiliar prescribers or high quantities using PDMP and documentation. Pharmacists should employ a decision framework: verify, document, and refuse if risks outweigh benefits to mitigate controlled substance errors.
20. In a hospital oncology unit, a 50-year-old female (63 kg) is ordered methotrexate 10 mg PO weekly for rheumatoid arthritis continuation while inpatient; the MAR displays "methotrexate 10 mg PO daily" due to a frequency selection error. Current meds: folic acid 1 mg PO daily, prednisone 5 mg PO daily, pantoprazole 40 mg PO daily. Labs: SCr 1.0 mg/dL, AST/ALT 38/41 U/L (mildly elevated), INR 1.0, A1c 5.9%; allergies: none. The risk is high-alert dosing frequency error causing severe toxicity. What is the most effective strategy to prevent this medication error?
    Answer: Implement weekly-only order sentences with hard-stop alerts for daily methotrexate (non-oncologic use) and require pharmacist verification of indication and frequency This question tests order entry safeguards for high-alert drugs like methotrexate to prevent frequency errors. The key risk element is daily instead of weekly dosing, causing toxicity in a rheumatoid arthritis patient on immunosuppressants. Implementing weekly-only orders with alerts and verification is the best choice as it blocks errors systemically. Allowing daily with monitoring or altering without input perpetuates risks, while instructing holds is unreliable. Changing dose independently violates protocols. A pearl is that high-alert drugs need hard-stop controls. Pharmacists should advocate for CPOE safeguards in risk management.

Start this quiz